Company news
Percheron Therapeutics Limited news in 2017
Percheron Therapeutics Limited's news releases, calls and decks from 2017, newest first.
ATL1103/atesidorsen Early Access Program Agreement
December 21, 2017
ATL1102 for MS and DMD Update
December 18, 2017
ATL1102 Black Hole MS data to be presented at MS Conference
August 29, 2017
ATL1102 for Multiple Sclerosis Phase IIb trial Update
July 26, 2017
Antisense Therapeutics to enter clincial development in DMD
June 26, 2017
ATL1102 for MS Phase IIb IND submitted to the FDA
June 25, 2017
Positive effects with ATL1102 on MS Black Hole lesions
June 15, 2017
ATL1103 Update
May 17, 2017
ATL1102 for MS Phase IIb Investigational New Drug Submission
April 23, 2017
Market and Technology Update
March 23, 2017
ATL1103 Patent Update
February 23, 2017
ATL1102 for MS - Progress Update
February 15, 2017